<DOC>
	<DOC>NCT00847197</DOC>
	<brief_summary>This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.</brief_summary>
	<brief_title>A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Participant is not on a statin or other lipidmodifying therapy Low or moderate risk participant Male participants, and female participants not of reproductive potential Female participant of reproductive potential Participant is pregnant, breastfeeding, or expecting to conceive during the study Participant has history of cancer within 5 years of study (except certain types of skin and cervical cancer) Participant is a user of recreational or illicit drugs or has a recent history of drug and/or alcohol abuse Participant has donated or received blood within 8 weeks of study start or intends to give/receive blood during the study Participant consumes more than 3 alcoholic drinks per day or more than 14 alcoholic drinks per week Participant is currently experiencing menopausal hot flashes Participant currently engages in vigorous exercise or an aggressive diet regimen Participant is at high risk for heart conditions Participant has Type 1 or Type 2 diabetes mellitus Participant has poorly controlled cardiac arrhythmias Participant has a history of stroke or other hemorrhage Participant has poorly controlled high blood pressure Participant has a thyroid condition or other endocrine/metabolic disease that would affect serum lipids Participant has a disease of the kidney or liver Participant has an ulcer within 3 months of screening Participant is Human Immunodeficiency Virus (HIV) positive Participant is taking cyclical hormonal contraceptives or noncontinuous hormone replacement therapy Participant is taking or has taken an Organic Anion Transporter (OAT1/3) inhibitor/substrate within 3 days of screening Participant has taken an antiobesity medication within 3 months of screening Participant is taking coumarins Participant is taking Nonsteroidal Antiinflammatory Drugs (NSAIDs) (acetaminophen and Cyclooxygenase2 (COX2) inhibitors are allowed) Participant is taking more than 100 mg aspirin per day Participant is being treated with oral, intravenous, or injected corticosteroids or anabolic agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>